Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH EBITDA Margin

EBITDA as a percentage of revenue.

Faeth Therapeutics, Inc.NASDAQ: FTH

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
4028.0%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's LTM Jun 2026 EBITDA Margin of 4028.0% is the highest of the 9 companies compared; the peer median is -397.5%.
FTH Competitors Peer median
EBITDA Margin for FTH and competitors
Company Period LTM level YoY 3-year change
FTHFaeth Therapeutics, Inc.LTM Jun 20264028.0% ——
PBYIPuma Biotechnology, Inc.LTM Mar 202619.8% -3.7 pp+13.8 pp
NUVBNuvation Bio Inc.LTM Jun 2026-74.8% +1326.6 pp—
TNGXTango Therapeutics, Inc.FY2025-159.2% +144.1 pp+269.3 pp
VSTMVerastem, Inc.LTM Mar 2026-387.1% +1063.3 pp+2084.9 pp
KURAKura Oncology, Inc.LTM Mar 2026-408.0% -146.3 pp—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
JANXJanux Therapeutics, Inc.LTM Mar 2026-520.3% +290.5 pp-393.5 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2742.3% +927.4 pp+20440.0 pp
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding FTH) -397.5%+609.0 pp+269.3 pp

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue685K1.81M571K551K0
Gross Profit(685K)(1.81M)(571K)(551K)0
Gross Margin—————
Research & Development21.66M29.58M18.3M18.63M10.96M
Selling, General & Admin15.14M17.73M18.77M12.49M11.33M
Operating Expenses36.8M47.31M36.49M31.11M22.29M
Depreciation & Amortization685K1.81M3.68M551K139K
EBITDA(35.44M)(46.56M)(33.39M)(29.52M)(20.91M)
EBITDA Margin—————
Operating Income(37.48M)(49.12M)(37.06M)(31.66M)(22.29M)
Operating Margin—————
Interest Income800K1.78M3.62M2.55M1.24M
Interest Expense670K219K144K90K32K
Other Income / Expenses688K532K2.96M1.51M1.2M
Income Before Tax(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Net Margin—————
EPS (Basic)(26.56)(31.65)(24.40)(24.01)(16.72)
EPS (Diluted)(26.56)(31.65)(24.40)(24.01)(16.72)
Weighted Avg Shares1.39M1.54M1.4M1.26M1.26M
Weighted Avg Shares (Diluted)1.39M1.54M1.4M1.26M1.26M

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.